BioPlus Acquisition Corp.: directors' dealings · United States · SEC (Form 4)

About BioPlus Acquisition Corp.

BioPlus Acquisition Corp. is a special purpose acquisition company (SPAC), meaning it was created as a publicly listed shell vehicle designed to complete a merger, share exchange, asset acquisition, or similar business combination with a private operating company. According to SEC filings, the company was incorporated on February 11, 2021 in the Cayman Islands and completed its initial public offering on the U.S. NASDAQ on December 7, 2021. Its SEC records also show a business address at 260 Madison Avenue, Suite 800, New York, NY 10016, United States. ([sec.gov](https://www.sec.gov/Archives/edgar/data/1856653/000119312522073378/d309509d10k.htm)) BioPlus was originally positioned as a healthcare-focused SPAC. In its public disclosures, the company said it would pursue targets in the healthcare industry, with a geographic reach that included the United States, Europe, Israel and Australasia. That framing supports a Health & Pharma sector tag, even though BioPlus itself does not operate as a traditional revenue-generating healthcare company. Instead, its business model is that of a capital markets platform: raise trust capital, identify a target, negotiate a transaction, and ultimately create a listed combined company. As such, the company’s investment case depends on deal execution rather than on product sales, clinical pipelines, or recurring operating margins. ([avertix.com](https://avertix.com/assets/press-releases/Avertix-SPAC-Termination-Release-FINAL_FOR_RELEASE.pdf)) Historically, the most material strategic development was BioPlus’s proposed business combination with Avertix Medical, Inc. (formerly Angel Medical Systems). SEC filings show that the parties entered into a business combination agreement on May 2, 2023, with the combined company expected to list on NASDAQ under a new ticker after closing. Avertix is a medical device company known for its Guardian system, an implantable cardiac warning platform intended to detect and alert patients to certain heart events. However, the transaction did not close: on October 4, 2023, the parties mutually terminated the agreement, and BioPlus disclosed its intention to liquidate and return cash to public shareholders as soon as practicable. That termination is the key recent event shaping the company’s profile. ([sec.gov](https://www.sec.gov/Archives/edgar/data/1856653/000119312523212329/d489625d10q.htm)) For investors, BioPlus should therefore be viewed as a NASDAQ-listed U.S.-related SPAC with a healthcare mandate, not as an operating medtech platform. Its competitive position historically rested on sponsor credibility, access to capital, and the ability to source an attractive healthcare target. The company’s public filings emphasize its early-stage nature and lack of operating revenues absent a business combination. In practical terms, the investment story is primarily one of transaction optionality and liquidation risk, rather than product commercialization or market-share expansion. ([sec.gov](https://www.sec.gov/Archives/edgar/data/1856653/000119312522073378/d309509d10k.htm))